171 related articles for article (PubMed ID: 25172457)
21. Infections associated with ruxolitinib: study in the French Pharmacovigilance database.
Sylvine P; Thomas S; Pirayeh E;
Ann Hematol; 2018 May; 97(5):913-914. PubMed ID: 29340760
[No Abstract] [Full Text] [Related]
22. Ruxolitinib.
Ajayi S; Becker H; Reinhardt H; Engelhardt M; Zeiser R; von Bubnoff N; Wäsch R
Recent Results Cancer Res; 2018; 212():119-132. PubMed ID: 30069628
[TBL] [Abstract][Full Text] [Related]
23. Occult hepatitis B infection reactivation after ruxolitinib therapy.
Perricone G; Vinci M; Pungolino E
Dig Liver Dis; 2017 Jun; 49(6):719. PubMed ID: 28410914
[No Abstract] [Full Text] [Related]
24. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
Heine A; Brossart P; Wolf D
Blood; 2013 Nov; 122(23):3843-4. PubMed ID: 24288410
[No Abstract] [Full Text] [Related]
25. Disseminated blastomycosis in a patient with polycythemia vera on ruxolitinib.
Zeitler K; Jariwala R; Alrabaa S; Sriaroon C
BMJ Case Rep; 2021 Nov; 14(11):. PubMed ID: 34725058
[TBL] [Abstract][Full Text] [Related]
26. The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.
Ikeda K; Ueda K; Sano T; Ogawa K; Ikezoe T; Hashimoto Y; Morishita S; Komatsu N; Ohto H; Takeishi Y
Intern Med; 2017; 56(13):1705-1710. PubMed ID: 28674362
[TBL] [Abstract][Full Text] [Related]
27. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report.
Colomba C; Rubino R; Siracusa L; Lalicata F; Trizzino M; Titone L; Tolomeo M
BMC Res Notes; 2012 Oct; 5():552. PubMed ID: 23039051
[TBL] [Abstract][Full Text] [Related]
28. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
Nazha A; Gerds AT
Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864
[TBL] [Abstract][Full Text] [Related]
29. Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature.
Tsukamoto Y; Kiyasu J; Tsuda M; Ikeda M; Shiratsuchi M; Ogawa Y; Yufu Y
Intern Med; 2018 May; 57(9):1297-1300. PubMed ID: 29279479
[TBL] [Abstract][Full Text] [Related]
30. Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
Pugliese N; Giordano C; Nappi D; Luciano L; Cerchione C; Annunziata M; Casale B; Crisà E; Villa MR; Pezzullo L; Iovine M; Picardi M; Grimaldi F; Pane F; Martinelli V
Cancer Med; 2019 Jun; 8(6):2802-2809. PubMed ID: 30997748
[TBL] [Abstract][Full Text] [Related]
31. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
Mesa RA; Kiladjian JJ; Catalano JV; Devos T; Egyed M; Hellmann A; McLornan D; Shimoda K; Winton EF; Deng W; Dubowy RL; Maltzman JD; Cervantes F; Gotlib J
J Clin Oncol; 2017 Dec; 35(34):3844-3850. PubMed ID: 28930494
[TBL] [Abstract][Full Text] [Related]
32. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N
Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854
[TBL] [Abstract][Full Text] [Related]
33. Iatrogenic Kaposi sarcoma in a patient treated with ruxolitinib: A case report.
Tourlaki A; Benzecry V; Veraldi S; Brambilla L
J Dermatol; 2020 Feb; 47(2):e38-e39. PubMed ID: 31829460
[No Abstract] [Full Text] [Related]
34. Epstein-Barr virus gastric ulcer associated with ruxolitinib.
Kusano Y; Terui Y; Ueda K; Hatake K
Ann Hematol; 2016 Oct; 95(10):1741-2. PubMed ID: 27411541
[No Abstract] [Full Text] [Related]
35. Elevation of the Hepatitis B Virus DNA during the Treatment of Polycythemia Vera with the JAK Kinase Inhibitor Ruxolitinib.
Kirito K; Sakamoto M; Enomoto N
Intern Med; 2016; 55(10):1341-4. PubMed ID: 27181544
[TBL] [Abstract][Full Text] [Related]
36. Ruxolitinib in clinical practice for therapy of myelofibrosis: single USA center experience following Food and Drug Administration approval.
Geyer H; Cannon K; Knight E; Fauble V; Camoriano J; Emanuel R; Tibes R; Mesa R
Leuk Lymphoma; 2014 Jan; 55(1):195-7. PubMed ID: 23647081
[No Abstract] [Full Text] [Related]
37. Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib.
Branco B; Metsu D; Dutertre M; Marchou B; Delobel P; Recher C; Martin-Blondel G
Ann Hematol; 2016 Jun; 95(7):1207-9. PubMed ID: 27113251
[No Abstract] [Full Text] [Related]
38. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.
Verstovsek S; Vannucchi AM; Griesshammer M; Masszi T; Durrant S; Passamonti F; Harrison CN; Pane F; Zachee P; Kirito K; Besses C; Hino M; Moiraghi B; Miller CB; Cazzola M; Rosti V; Blau I; Mesa R; Jones MM; Zhen H; Li J; Francillard N; Habr D; Kiladjian JJ
Haematologica; 2016 Jul; 101(7):821-9. PubMed ID: 27102499
[TBL] [Abstract][Full Text] [Related]
39. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
[TBL] [Abstract][Full Text] [Related]
40. Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature.
Dioverti MV; Abu Saleh OM; Tande AJ
Infect Dis (Lond); 2018 May; 50(5):381-387. PubMed ID: 29251529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]